Contrasting Mannatech (NASDAQ:MTEX) and Amylyx Pharmaceuticals (NASDAQ:AMLX)
by Teresa Graham · The Cerbat GemAmylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Mannatech (NASDAQ:MTEX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Insider & Institutional Ownership
95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Amylyx Pharmaceuticals and Mannatech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $87.37 million | 14.35 | -$301.74 million | ($1.80) | -6.34 |
| Mannatech | $117.87 million | 0.13 | $2.49 million | ($0.86) | -9.71 |
Mannatech has higher revenue and earnings than Amylyx Pharmaceuticals. Mannatech is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Amylyx Pharmaceuticals has a beta of -0.31, meaning that its stock price is 131% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Amylyx Pharmaceuticals and Mannatech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 1 | 2 | 9 | 2 | 2.86 |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
Amylyx Pharmaceuticals currently has a consensus target price of $17.25, indicating a potential upside of 51.05%. Given Amylyx Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Mannatech.
Profitability
This table compares Amylyx Pharmaceuticals and Mannatech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -68.95% | -61.52% |
| Mannatech | -1.50% | -22.75% | -4.75% |
Summary
Amylyx Pharmaceuticals beats Mannatech on 8 of the 15 factors compared between the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.